{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:14:33Z","timestamp":1761884073134,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.reumae.2022.03.008","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T10:55:42Z","timestamp":1681383342000},"page":"204-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study"],"prefix":"10.1016","volume":"19","author":[{"given":"Jordi","family":"Gratac\u00f3s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7229-6005","authenticated-orcid":false,"given":"Jos\u00e9 L.","family":"Pablos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-1964","authenticated-orcid":false,"given":"Eugenio","family":"de Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5998-6300","authenticated-orcid":false,"given":"Xavier","family":"Juanola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-4944","authenticated-orcid":false,"given":"Cristina","family":"Fern\u00e1ndez-Carballido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-0252","authenticated-orcid":false,"given":"Rafael","family":"Ariza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-9293","authenticated-orcid":false,"given":"Pau","family":"Terradas-Montana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1577-7838","authenticated-orcid":false,"given":"Carlos","family":"Sastr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-0265","authenticated-orcid":false,"given":"Cristina","family":"Sanabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2022.03.008_bib0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.reumae.2022.03.008_bib0160","unstructured":"Sociedad Espa\u00f1ola de Reumatolog\u00eda. Grupo de trabajo espogu\u00eda. Gu\u00eda de pr\u00e1ctica cl\u00ednica para el tratamiento de la espondiloartritis axial y la artritis psori\u00e1sica (in spanish); 2018. Available from: https:\/\/www.ser.es\/wp-content\/uploads\/2016\/03\/ESPOGUIA-actualizaci%C3%B3n-2017_DEF_web.pdf [accessed 30.07.20]."},{"key":"10.1016\/j.reumae.2022.03.008_bib0165","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2022.03.008_bib0170","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/bjd.12748","article-title":"Diagnosing and treating psoriatic arthritis: an update","volume":"170","author":"Boehncke","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0175","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.reuma.2017.08.007","article-title":"Recommendations of the spanish society of rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis","volume":"14","author":"Torre Alonso","year":"2018","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2022.03.008_bib0180","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the darea\/dapsa score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2022.03.008_bib0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3899\/jrheum.170449","article-title":"Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature","volume":"45","author":"Gossec","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0190","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"Eular recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2022.03.008_bib0195","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (ticopa): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.reumae.2022.03.008_bib0200","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jdv.16104","article-title":"A belgian consensus on the definition of a treat-to-target outcome set in psoriasis management","volume":"34","author":"Grine","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0205","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001083","article-title":"Treat-to-target in PsA: methods and necessity","author":"Dures","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2022.03.008_bib0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-018-0781-x","article-title":"Novel concepts in psoriatic arthritis management: can we treat to target?","volume":"20","author":"Tucker","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.reumae.2022.03.008_bib0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-019-04248-1","article-title":"Real-world evidence in rheumatic diseases: relevance and lessons learnt","volume":"39","author":"Misra","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2022.03.008_bib0220","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2022.03.008_bib0225","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the dapsa score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2022.03.008_bib0230","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2022.03.008_bib0235","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.semarthrit.2020.03.015","article-title":"Comparison of remission and low disease activity states with dapsa, mda and vlda in a clinical trial setting in psoriatic arthritis patients: 2-year results from the future 2 study","volume":"50","author":"Coates","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2022.03.008_bib0240","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3899\/jrheum.181313","article-title":"The assessment of disease activity in psoriatic arthritis: Mda, vlda, dapsa, or something else?","volume":"46","author":"Lubrano","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0245","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40744-019-00171-w","article-title":"Sustained very low disease activity and remission in psoriatic arthritis patients","volume":"6","author":"Lubrano","year":"2019","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.reumae.2022.03.008_bib0250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/annrheumdis-2016-209511","article-title":"Disease activity states of the dapsa, a psoriatic arthritis specific instrument, are valid against functional status and structural progression","volume":"76","author":"Aletaha","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2022.03.008_bib0255","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3899\/jrheum.170112","article-title":"Comparison of composite indices tailored for psoriatic arthritis treated with csdmard and bdmard: a cross-sectional analysis of a longitudinal cohort","volume":"44","author":"Lubrano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0260","doi-asserted-by":"crossref","first-page":"710","DOI":"10.3899\/jrheum.180460","article-title":"Very low disease activity, dapsa remission, and impact of disease in a spanish population with psoriatic arthritis","volume":"46","author":"Queiro","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0265","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3899\/jrheum.160386","article-title":"Defining low disease activity states in psoriatic arthritis using novel composite disease instruments","volume":"43","author":"Lubrano","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-017-1277-1","article-title":"Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study","volume":"19","author":"Queiro","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2022.03.008_bib0275","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acr.22529","article-title":"Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis","volume":"67","author":"Haddad","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.reumae.2022.03.008_bib0280","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3899\/jrheum.150805","article-title":"Minimal disease activity and remission in psoriatic arthritis patients treated with anti-tnf-\u03b1 drugs","volume":"43","author":"Perrotta","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0285","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.reumae.2022.03.008_bib0290","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.reumae.2022.03.008_bib0295","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3899\/jrheum.141359","article-title":"Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study","volume":"43","author":"Haque","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2022.03.008_bib0300","first-page":"685","article-title":"Actualidades en artritis psori\u00e1sica 2020","volume":"64","author":"Elizondo-Leal","year":"2020","journal-title":"Dermatol Rev Mex"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574323000357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574323000357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:02:21Z","timestamp":1761879741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574323000357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2173574323000357"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2022.03.008","relation":{},"ISSN":["2173-5743"],"issn-type":[{"type":"print","value":"2173-5743"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease control in patients with psoriatic arthritis in real clinical practice in Spain: MiDAS study","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2022.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}